Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like <b>Elon Musk's</b> Biotech Quietly Nabs $27 Million to Stick Machines Into People's Brains August 27, 2017 3 Marijuana Biotech Stock Winners for 2018 December 21, 2017 Sanofi's Rumored Buyout Target Flexion Shows Off Mid-Stage Osteoarthritis Data June 11, 2017
<b>Elon Musk's</b> Biotech Quietly Nabs $27 Million to Stick Machines Into People's Brains August 27, 2017
